The POWER II (Pre-Operative Window of Endocrine Therapy to Inform Radiation Therapy Decisions) trial is a randomized, Phase III study designed for women ages 65 and older with early-stage, estrogen receptor-positive (ER+) breast cancer. Riverside Regional Medical Center will participate in the study as part of UVA Health’s clinical trials network.
Participants will be randomly assigned to one of two groups:
- Group 1: 90 days of pre-ET before breast cancer surgery (may have 1-2 extra clinic visits and 1 planned phone call)
- Group 2: Breast cancer surgery without pre-ET
After surgery, all participants will decide with their doctors about whether to receive radiation and/or endocrine therapy. Before and after surgery, participants in both groups will fill out surveys that ask questions about how they tolerate medications and their feelings about their medical care choices. Participants in both groups will be followed for 2 years after surgery.
All study related treatments are standard of care. Participants and/or their insurance company will be billed for medication, tests, and procedures that take place throughout the study
Principal Investigator
Magi Khalil, MD, PhD
Contact
Riverside Oncology Clinical Research
[email protected]
Locations
Riverside Peninsula Cancer Institute and Infusion Center Gloucester
7544 Medical Drive, B-1, Gloucester, VA 23061
Riverside Peninsula Cancer Institute and Infusion Center Newport News
12100 Warwick Boulevard, 201-B, Newport News, VA 23601
Status
Recruiting
ClinicalTrials.gov ID: NCT06507618